IBio Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:3em;'>IBI</div>
IBIO -- USA Stock  

USD 1.46  0.01  0.68%

IBio Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 100.39 Million. Working Capital is expected to rise to about 61 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (12.7 M). One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will outline IBio. We currently estimate IBio as undervalued. The real value is approaching 2.08 per share.
Published over a week ago
View all stories for IBio | View All Stories
Are IBio (NYSEMKT:IBIO) conflicting basic indicators contributing to the latest slide?
We provide advice to complement the regular expert consensus on IBio. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at this particular time. IBio dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include IBio income statement, its balance sheet, and the statement of cash flows. Potential IBio investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although IBio investors may use each financial statement separately, they are all related. The changes in IBio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on IBio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of IBio fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of IBio performance into the future periods or doing a reasonable stock valuation. The intrinsic value of IBio shares is the value that is considered the true value of the share. If the intrinsic value IBio is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares IBio. Please read more on our fundamental analysis page.

Watch out for price decline

Please consider monitoring IBio on a daily bases if you are holding a position in it. IBio is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as IBio stock to be traded above the $1 level to remain listed. If IBio stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

What is IBio Asset Breakdown?

IBio Inc reports assets on its Balance Sheet. It represents the amount of IBio resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect IBio volatility, please check the breakdown of all its fundamentals

How IBio utilizes its cash?

To perform a cash flow analysis of IBio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash IBio is receiving and how much cash it distributes out in a given period. The IBio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. IBio Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (13.7 Million)

IBio Gross Profit

IBio Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing IBio previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show IBio Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Acquisition by Robert Kay of 400000 shares of IBio subject to Rule 16b-3

Legal trades by IBio insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
IBio insider trading alert for grant of stock option by Robert Kay, the corporate stakeholder, on 28th of October 2020. This event was filed by Ibio Inc with SEC on 2020-10-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down IBio Indicators

The company reported the previous year's revenue of 1.64 M. Net Loss for the year was (38.26 M) with profit before overhead, payroll, taxes, and interest of 1.64 M.
 2017 2018 2019 2020 (projected)
Interest Expense1.92 M1.9 M2.47 M2.66 M
Gross Profit444 K2.02 M1.64 M1.46 M

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. IBio has an asset utilization ratio of 3.18 percent. This suggests that the company is making $0.0318 for each dollar of assets. An increasing asset utilization means that IBio Inc is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
66.6 M
Assets Non Current
35 M
Current Assets66.62 Million64.56
Assets Non Current35 Million33.92
Goodwill1.58 Million1.53

Can IBio build up on the latest rise?

The maximum drawdown is down to 40.57 as of today. IBio Inc is displaying above-average volatility over the selected time horizon. Investors should scrutinize IBio Inc independently to ensure intended market timing strategies are aligned with expectations about IBio volatility.

Our Conclusion on IBio

Whereas some other companies in the biotechnology industry are either recovering or due for a correction, IBio may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 15th of November 2020, our analysis shows that IBio moves totally opposite to the market. The company is undervalued and projects low odds of distress for the next 2 years. However, our primary 30 days 'Buy-vs-Sell' recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of IBio Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com